愈创甘油醚(Guaifenesin) - 在研适应症：咳嗽，排痰困难，呼吸系统疾病_专利_临床

概要

基本信息

简介愈创甘油醚于1949年在日本批准上市，是一种祛痰药物，存在于许多非处方产品中。通常以商品名Mucinex®出售，该药的作用机制尚不完全清楚。它被认为通过稀释和松弛气道中的粘液起作用，使其更容易咳出并缓解充血。作为祛痰药，愈创甘油醚被广泛用于缓解各种呼吸系统疾病（包括支气管炎和普通感冒）引起的咳嗽和胸闷的症状。这种药物有多种剂型，包括片剂、胶囊和糖浆，并且通常与其他药物结合使用以治疗特定症状。虽然通常是安全的，但愈创甘油醚可能会引起头晕、嗜睡和胃部不适等副作用。

药物类型

小分子化药

别名

Glyceryl guaiacolate、Guaifenesin (JP17/USP/INN)、Guaifenesine

+ [11]

靶点-

作用方式-

作用机制-

治疗领域

呼吸系统疾病

在研适应症

咳嗽排痰困难呼吸系统疾病

非在研适应症

急性下呼吸道感染急性呼吸道感染急性上呼吸道感染+ [3]

原研机构

Kyoto Pharmaceutical Industries Ltd.

在研机构

RB Health (US) LLC

Kyoto Pharmaceutical Industries Ltd.

Lovelace Respiratory Research Institute

非在研机构

Reckitt Benckiser, Inc.

Reckitt Benckiser LLC安徽省医药科技实业公司

+ [1]

权益机构-

最高研发阶段批准上市

首次获批日期

日本 (1949-03-20),

咳嗽排痰困难

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C10H14O4

InChIKeyHSRJKNPTNIJEKV-UHFFFAOYSA-N

CAS号93-14-1

关联

31

项与愈创甘油醚相关的临床试验

NCT06716645

/ Completed临床4期

A Real-World Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin

The purpose of this Real-World Evidence study is to generate real world data from participants with cough associated with the common cold, evaluating the effects in two arms with commercially available cough syrups on health-related quality of life (QoL). Arm 1 includes one cough syrup (which can be used day or night) and Arm 2 includes the daytime cough syrup and a nighttime cough syrup.

开始日期2024-12-04

申办/合作机构

Haleon Plc

CTR20232759

/ CompletedN/A

愈创木酚甘油醚双层缓释片人体生物等效性研究

采用单中心、随机、开放、双周期交叉、单次口服试验设计比较空腹和餐后给药条件下，北京柏雅联合药物研究所有限公司提供的愈创木酚甘油醚双层缓释片（600 mg）与RB HEALTH US LLC生产的愈创木酚甘油醚双层缓释片（600 mg，商品名：Mucinex®）在中国健康人群吸收程度和吸收速度的差异，并评价北京柏雅联合药物研究所有限公司提供的愈创木酚甘油醚双层缓释片的安全性。

开始日期2023-10-04

申办/合作机构

北京柏雅联合药物研究所有限公司

NCT05843669

/ Completed临床4期

An Open-label, Multicenter, Single-group Study to Evaluate the Effects of Long-term Use of Mucinex® in Patients With Stable Chronic Bronchitis.

This is an open-label, multicenter, single-group study designed to determine the effectiveness of Mucinex® when used by patients to treat SCB over a 12-week period, following a 2-week run-in period of no treatment (to establish a baseline).

开始日期2023-07-17

申办/合作机构

American Health Research, LLC

[+1]

100 项与愈创甘油醚相关的临床结果

登录后查看更多信息

100 项与愈创甘油醚相关的转化医学

登录后查看更多信息

100 项与愈创甘油醚相关的专利（医药）

登录后查看更多信息

1,084

项与愈创甘油醚相关的文献（医药）

2025-10-01·Drug Testing and Analysis

Pooled Sampling Technique to Improve the Monitoring of Medication Use in the Racehorse Industry

Article

作者: Chambers, Adam

ABSTRACT:

All anti‐doping programmes face financial constraints and monitoring trends in medication use or abuse in a population of racehorses can be difficult and expensive. Obtaining biological samples is the primary method of anti‐doping control in individual horses or stables of horses but can be invasive and expensive. Another important practice of anti‐doping control has been the confiscation of used and filled syringes by regulators for individual forensic analysis. Pooled samples testing involves the testing of multiple individual samples together as one composite sample. This pooled sample approach has been employed to gather information concerning populations' exposure to substances and infectious agents including the analysis of samples of wastewater (a large, pooled sample) that have been used during the pandemic to monitor the presence of new COVID variants. Moreover, pooled samples of urine and wastewater have been used to monitor for recreational drug use and for the presence of new psychoactive substances in cities and large events. This approach has been credited with providing timely insight in the trends of illicit drugs use. To be effective, an anti‐doping programme should not be predictable to avoid being defeated by countermeasures; therefore, the implementation of new methods is considered essential. A new pooled sampling technique using confiscated groups of used syringes and needles including biomedical sharps containers obtained from veterinarians and other horse racing industry participants has been employed over several years in Ontario, Canada. These containers held needles used to administer substances to racehorses along with syringes and other debris. The analysis of the wash provided a timely insight of medications being administered in horses, and substances present at racetracks and training centres including substances predominantly of human use and abuse. Sharp containers confiscated from veterinarians and trainers provided insight into injectable medications administered at numerous stables and to hundreds of horses.

2025-10-01·ARCHIV DER PHARMAZIE

Chemometrics‐Assisted Spectrophotometric Methods for Determination of Methocarbamol and Paracetamol Along With Two Related Impurities: An Environmental Sustainability Assessment

Article

作者: Essam, Hebatallah M. ; Bassuoni, Yasmine F. ; Kelani, Khadiga M. ; Mohamed, Ahmed R.

ABSTRACT:

Two multivariate calibration models were created for the concurrent estimation of methocarbamol and paracetamol in their co‐formulated pharmaceutical dosage form. These methods also enabled the detection of their impurities, p‐aminophenol and guaifenesin. The calibration paradigms, based on principal component regression (PCR) and partial least squares (PLS), were employed to assess the drugs and their impurities. The methods demonstrated accurate simultaneous determination of methocarbamol, paracetamol, p‐aminophenol, and guaifenesin within the concentration ranges of 20.00–80.00 µg mL−1 for methocarbamol, 20.00–60.00 µg mL−1 for paracetamol, 0.06–4.00 µg mL−1 for p‐aminophenol, and 0.08–10.00 µg mL−1 for guaifenesin. The techniques were evaluated in accordance with ICH directions, and the outcomes confirmed the reliability and validity of the developed methods. The suggested approaches were successfully applied to analyze methocarbamol and paracetamol in their combined tablets and to quantify their related impurities. Furthermore, the environmental impact of these techniques was evaluated using a variety of metrics, assessing their greenness and whiteness alongside their practical effectiveness (blueness), with the results highlighting their superior environmental performance. Additionally, the suggested techniques' sustainability was appraised using the recently introduced NQS index, yielding a score of 67.70%, demonstrating strong alignment with sustainable analytical practices.

2025-08-01·VETERINARY SURGERY

Clinical findings and outcomes of eight dogs with surgically treated frontal sinus mucoceles

Article

作者: Moore, Talisha ; Darrow, Brett ; Tobias, Karen M. ; DePompeo, Christine ; Ogden, Jessica ; Cole, Grayson

Abstract:

Objective:

To report clinical findings and outcomes of dogs surgically treated for frontal sinus mucocele.

Study design:

Short case series.

Animals:

Eight dogs.

Methods:

Seven of eight dogs had evidence of previous skull trauma and developed clinical signs by 10 months of age. On computed tomography, all dogs had a fluid‐attenuating, expansile lesion within the frontal sinus and multicentric bone erosion. Surgical treatments comprised frontal sinusotomy and debridement, with either stenting of nasofrontal openings or removal of all sinus lining, with or without fat graft ablation.

Results:

Four dogs were clinically normal 10–70 months after surgery; two of these dogs had developed swelling 1.5–3 months after surgery, which resolved within 4 months, and one temporarily developed nasal discharge 1 month after stent removal. The mucocele recurred in four dogs 1 to 9 months after surgery; three of those dogs underwent a second surgery with nasofrontal stenting. Two of those dogs were clinically normal at 6 or 20 months after the second surgery. Owners of the third dog reported intermittent swelling for 16 months after the second surgery, which was managed with guaifenesin and carprofen or prednisone. Overall, resolution occurred in one dog with debridement and fat graft ablation and in five dogs with nasofrontal stenting.

Conclusion:

Young dogs with skull trauma may develop aseptic sinus mucoceles that cause facial distortion and compression of surrounding structures. Re‐establishment of sinus drainage or ablation of the lining may resolve clinical signs; however, multiple surgeries may be required.

30

项与愈创甘油醚相关的新闻（医药）

2025-10-16

·ETPharma

Under the scanner, yet generic cough syrups hit shelves

Mumbai: Tamil Nadu-based Sresan Pharmaceuticals ' cough syrup brand Coldrif that allegedly caused the deaths of more than 20 children in Madhya Pradesh is among thousands of generic cough syrup brands currently available in the domestic market, thriving below the regulatory radar. In less than a fortnight, cough syrups from at least three companies Sresan, Rednex and Shape Pharma have been found to contain diethylene glycol, an industrial solvent known to be poisonous and prohibited for use in producing medicines. However, this could just be the tip of the iceberg. Difficult to Capture Data PharmaTrac , a leading prescription audit firm, has coverage on sales of about 1,150 cough syrup brands in India, but sector experts believe the market is extremely fragmented and the actual count could be twice as much. Cough and cold syrups, popular fever drugs, or pain and inflammation medicines are among the most aggressively marketed to doctors by small and regional pharma companies . "Incentives by smaller and regional companies sway the decisions of the doctors (to prescribe) more than the reputation of brands," said a senior area manager in a Mumbai-based pharma company. "In addition, in small towns, less than 100 kms from Mumbai, a shop chemist can recommend a brand of a drug to the customer." Retail-level data and trends for such small companies is not captured by audit firms like PharmaTrac as they are either insignificant in size or operate in regions beyond these firms' coverage area. Sresan's Coldrif does not figure in the sales audits of PharmaTrac. Though data for small pharma units is unavailable, sales of cough and cold syrups in India have risen 30% to ₹3,423 crore from ₹2,627 crore over the last five years outpacing the average pharma industry growth rate of 8-10%, showed data from PharmaTrac. While unethical trade practices are a major factor, sales of cough and cold syrups are also being fuelled by rapid urbanisation, air pollution, and frequent weather changes triggering dust allergies and respiratory distress across age groups though it is more pronounced in children. Besides, irrational fixed dose combinations are being pumped into the market by small companies despite a sweeping crackdown a few years ago, and a ban on hundreds of cough syrup brands. Regional Disparity Inefficient oversight of state Food and Drug Administrators (FDAs) have helped unscrupulous companies to swamp the market with irrational combinations. In 2023, out of 14 irrational drugs banned for sale by the central drug administration, 13 were combinations for the treatment of cough, cold, asthma, and respiratory infections. These included amoxycillin + bromhexine + dextromethorphan, chlorpheniramine maleate + codeine and dextromethorphan + chlorpheniramine + guaifenesin + ammonium chloride. Leading drugmakers are capitalising on the growth potential. Pfizer 's Corex DX is at the top of the heap with sales of ₹266 crore (moving annual total September 2025), followed by AsthaKind DX from Mankind Pharma at ₹129 crore. However, the competition intensifies from the third slot with Maxtra of Emcure Pharma garnering ₹128 crore and Abbott's Tossex at ₹114 crore. Interestingly, as per PharmaTrac data, at least 600 cough syrup brands have not registered any sales during the year. The sales of cough syrup brands also highlighted regional disparity. PharmaTrac data showed Bihar and Jharkhand are the biggest cough syrup consuming states with sales of ₹315 crore. By Vikas Dandekar ,

2025-10-02

·ETPharma

Cough syrup linked with child’s death in Sikar neither prescribed nor supplied to district: Govt Official

New Delhi: The Rajasthan government has said claims of a 5-year-old child’s death allegedly caused due to a cough syrup is inconsistent with facts and a drug test to confirm the root cause of the tragedy is awaited. The cough syrup allegedly linked to the death of the child in Rajasthan’s Sikar district was neither prescribed by the attending doctor nor supplied to the Community Health Centre (CHC) in the district, a senior state health ministry official involved in the investigation told ETPharma. “Based on the initial probing we found that the cough syrup identified as Dextromethorphan linked with the death of a child was neither prescribed by the doctor and nor the medicine has been supplied to the Jhunjhunu district,” said the senior state government official on grounds of anonymity. Additionally, the child and his family members did not visit the Community Health Centre (CHC) on September 26, the date on which he is reported to have received and consumed the syrup, the official added. Earlier this week multiple reports outlined that, a child identified as Nityansh Sharma from Sikar district fell ill and subsequently died after consuming Dextromethorphan Hydrobromide syrup obtained from Chirana Community Health Centre (CHC) under the state's free medicine scheme "Mukhyamantri Nishulk Dava Yojana.” A day after the incident another three-year-old child in the state’s Bharatpur district is reported to have experienced similar complications after allegedly consuming the same syrup. However, according to the official, under the state government’s free medicine scheme the Dextromethorphan syrup is “not supplied to Jhunjhunu district” so the claim of obtaining the medicine from there is not consistent with facts. Bharatpur and Sikar are part of Jaipur Division, while Chirana is a village situated in Nawalgarh Tehsil of Jhunjhunu district in Rajasthan. Soon after the incident came to light, State Health Minister Gajendra Singh Khimsar ordered a probe to investigate the safety of medicine. Without disclosing the medicines prescribed to the deceased, the official quoted above said, “the child visited a doctor on September 22 and the prescription does not include Dextromethorphan.” The official said that the medicine was supplied to “several districts.” However, the case is linked to a particular batch, samples of which have been collected and sent to the state drug testing laboratory for analysis. According to the official, certain side effects of Dextromethorphan, such as dizziness and vomiting, are common and may be aggravated in cases of overdose or when taken alongside multiple medicines. “In this case (Nityansh), we cannot confirm that the death was caused by the cough syrup, as the family did not allow a post-mortem examination and before arriving on any conclusion here we are awaiting for the drug test report,” he said. Meanwhile as a precautionary measure, the supply and distribution of “all other batches of the drug have been halted across the state," it added. To expedite the investigation, the official stated that the laboratory test, which usually takes “8-10 days’, has been fast-tracked, and the report is expected by “tomorrow”, i.e. October 2, 2025 Calls made by ETPharma to Rajasthan State Drug regulatory officials remained unanswered. The state government has constituted a three-member committee to assess the test findings and decide on subsequent measures. Regarding any punitive action against the cough syrup manufacturer, Kayson Pharma, the official said that state authorities are preparing a notice to be sent to the company. However, any “strict action” will be taken only after the test report is received. While the official refrained from commenting on the purported manufacturing concerns related to the matter it explained that, “the procurement for the state’s free medicine scheme is overseen by the Rajasthan Medical Services Corporation Limited (RMSC) and all drug batches undergo quality testing in NABL-certified labs before being supplied for distribution to various CHCs.” Notably, in June 2023 the Central Drugs Standard Control Organization (CDSCO) had banned several Fixed-Dose Combinations (FDC) of Dextromethorphan citing "safety and quality concerns" with the drugs. The list includes several FDC combinations marketed as a syrup for cough such as Bromhexine + Dextromethorphan + Ammonium Chloride + Menthol; Dextromethorphan + Chlorpheniramine + Guaiphenesin + Ammonium Chloride, among several others. The drug linked with the case in Rajasthan involves a single ingredient: "Dextromethorphan." By Abhijeet Singh ,

2025-02-26

·米内网

咳嗽感冒“药王”易主！TOP20大洗牌，华润三九、葵花上榜，福元、康芝……冲击首仿

精彩内容近日，咳嗽和感冒化药市场波澜再起。安徽四环科宝制药的盐酸氨溴索口服溶液、海南全星制药的氨溴特罗口服溶液等5个产品同日获批，今年以来已有12个品规产品获批上市。米内网数据显示，咳嗽和感冒化药在2024年Q1-Q3中国零售药店终端销售额同比增长近15%。TOP20大洗牌，“药王”易主，华润三九、葵花上榜。2个改良型新药火热来袭，康芝药业、北京福元医药、合肥国药诺和药业等冲击首仿。大涨近15%，吴太医药、亚洲制药、华润三九位居前三近年中国零售药店终端咳嗽和感冒化药销售情况（单位：万元）来源：米内网格局数据库米内网数据显示，咳嗽和感冒化药在近年中国零售药店（城市实体药店和网上药店）终端均保持60亿元以上的销售规模，2024年Q1-Q3同比增长近15%。其中，城市实体药店是主要销售渠道，网上药店增速高于城市实体药店。从治疗小类来看，感冒复方制剂市场份额占比最大，超过60%；其次是祛痰药（不包括含止咳药的复方制剂）和止咳药与祛痰药的复方制剂均超过10%。 2024年Q1-Q3中国零售药店终端咳嗽和感冒化药集团TOP5来源：米内网格局数据库从集团TOP20格局来看，吴太医药、亚洲制药、华润三九、葵花药业、韩美药品位居前五，赫力昂和湖北凤凰白云山药业增速均超过50%。从在销品种数量来看，涉及产品超过200个，品牌超过1300个。 TOP20大洗牌！“药王”易主，华润三九、葵花上榜 2024年Q1-Q3中国零售药店终端咳嗽和感冒化药产品TOP20（单位：亿元）来源：米内网格局数据库注：销售额不足1亿元以*表示产品TOP20中，10个销售额超过1亿元，复方氨酚烷胺片登上“销冠”宝座，小儿氨酚黄那敏颗粒和氨咖黄敏胶囊是在销企业数均超过150家。 5个独家产品，分别为桉柠蒎肠溶胶囊（北京远大九和药业）、复方氨酚肾素片（香港幸福医药）、酚麻美敏片（强生）、乙酰半胱氨酸片（赞邦）、复方氨酚溴敏胶囊（澳美制药），桉柠蒎肠溶胶囊（北京远大九和药业）是唯一一个销售额超过1亿元的独家产品。 11个产品有双位数增速，复方氢溴酸右美沙芬糖浆、氨酚咖那敏片、复方氨酚那敏颗粒均超过50%，复方氨酚溴敏胶囊则重返TOP20之列。 2024年Q1-Q3中国零售药店终端咳嗽和感冒化药品牌TOP20（单位：亿元）来源：米内网格局数据库注：销售额不足1亿元以*表示品牌TOP20中，6个销售额超过1亿元，吉林省吴太感康药业的复方氨酚烷胺片、浙江亚峰药厂的复方氨酚烷胺胶囊、韩美的氨溴特罗口服溶液位居前三。从增速来看，华润三九(南昌)药业的盐酸氨溴索口服溶液翻倍，同比增长达137.47%；10个品牌有双位数增速，分别是吉林省吴太感康药业的复方氨酚烷胺片（28.18%）、浙江亚峰药厂的复方氨酚烷胺胶囊（21.88%）和小儿氨酚黄那敏颗粒（14.56%）、华润三九(黄石)药业的小儿氨酚黄那敏颗粒（11.58%）、中美天津史克制药的氨酚咖那敏片（57.13%）、香港幸福医药的复方氨酚肾素片（15.31%）、强生的右美沙芬愈创甘油醚糖浆（39.71%）、华润三九(北京)药业的小儿氨酚黄那敏颗粒（14.78%）、江西铜鼓仁和制药的复方氨酚烷胺胶囊（17.51%）、韩美的盐酸氨溴索口服溶液（24.04%）。近年中国零售药店终端复方氨酚烷胺片销售情况（单位：万元）来源：米内网格局数据库复方氨酚烷胺片为复方制剂，能缓解普通感冒和流感引起的发烧、鼻塞、全身酸痛等症状。该产品在2024年Q1-Q3中国零售药店终端销售规模超过7亿元，是咳嗽和感冒化药TOP1产品，吉林省吴太感康药业的市场份额最大。从细分渠道来看，城市实体药店是主要销售渠道，网上药店则快速增长，增速达82.18%，销售额已超过2023年全年。近年中国零售药店终端桉柠蒎肠溶胶囊销售情况（单位：万元）来源：米内网格局数据库桉柠蒎肠溶胶囊为黏液溶解性祛痰药，适用于急慢性支气管炎、肺炎、支气管扩张肺脓肿、肺部真菌感染、肺结核和矽肺等呼吸道疾病。该产品是北京远大九和药业的独家品种，在近年中国零售药店终端销售规模持续扩容，2024年Q1-Q3超过1亿元，同比增长5.21%。资料显示，北京远大九和药业作为远大医药核心战略板块之一，公司在售产品覆盖鼻炎、支气管炎、肺炎、哮喘、慢性阻塞性肺部疾病等，在呼吸疾病治疗领域已形成了较为完备的产品组合。其中，核心产品桉柠蒎肠溶胶囊获得多项指南和专家共识的明确推荐。 2个改良型新药火热来袭，福元、康芝……冲击首仿 2025年02月25日药品批准证明文件送达信息 2月25日，国家药监局官网显示，安徽四环科宝制药的盐酸氨溴索口服溶液、海南全星制药的氨溴特罗口服溶液、吉林省西点药业的氨溴特罗口服溶液等5个咳嗽和感冒化药同日获批。今年以来，咳嗽和感冒化药已有12个品规产品获批上市，14个受理号报产在审。截至目前，咳嗽和感冒化药有超过200个受理号报产在审，涉及超过20个产品。其中，氨溴特罗口服溶液竞争最为激烈，有35家企业报产；羧甲司坦干糖浆、左羟丙哌嗪糖浆、枸橼酸苯海拉明布洛芬片、愈创甘油醚双层缓释片、吸入用盐酸溴己新溶液、乙酰半胱氨酸片、乙酰半胱氨酸口服溶液、羧甲司坦糖浆国内暂无仿制药获批，康芝药业、北京福元医药、合肥国药诺和药业等企业有望拿下首仿。咳嗽和感冒化药新药报产在审情况来源：米内网中国申报进度（MED）数据库此外，2个改良型新药报产在审，分别是华润三九的盐酸氨溴索(冻干)口崩片和博志研新泰州药物技术的BCM347口溶膜。资料来源：米内网数据库、公司公告等注：米内网《中国城市实体药店药品终端竞争格局》，统计范围是：全国地级及以上城市实体药店，不含县乡村药店；《中国网上药店药品终端竞争格局》，统计范围是：全国网上药店所有药品数据，包括天猫、京东等第三方平台及私域平台上所有网上药店药品数据；上述销售额以产品在终端的平均零售价计算。免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。内容如有疏漏，欢迎沟通指出。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

上市批准

100 项与愈创甘油醚相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00337	愈创甘油醚	R05CA03	DB00874

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
咳嗽	日本	Kyoto Pharmaceutical Industries Ltd.	1949-03-20
排痰困难	日本	Kyoto Pharmaceutical Industries Ltd.	1949-03-20

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性上呼吸道感染	临床3期	美国	Reckitt Benckiser LLC	2011-09-01
急性上呼吸道炎症	临床3期	美国	Reckitt Benckiser LLC	2011-09-01
急性呼吸道感染	临床2期	美国	Reckitt Benckiser LLC	2010-04-01
急性下呼吸道感染	临床2期	美国	Reckitt Benckiser, Inc.	2009-12-01
普通感冒	临床2期	美国	Reckitt Benckiser, Inc.	2009-12-01
痰咳	临床1期	-	Reckitt Benckiser, Inc.	2009-06-30
呼吸系统疾病	临床前	美国	Lovelace Respiratory Research Institute	2012-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01364467 (CTgov)	临床2期	慢性鼻炎	30	Placebo (Placebo)	鬱淵憲鑰鹽餘艱遞夢膚(鑰獵窪糧廠選顧衊獵窪) = 繭積鑰鹽製壓夢鬱艱廠選積壓夢鹹鑰襯艱選淵 (獵衊衊淵積衊壓網襯糧, 0.59) 更多	-	2020-04-24
				Guaifenesin (Guaifenesin)	鬱淵憲鑰鹽餘艱遞夢膚(鑰獵窪糧廠選顧衊獵窪) = 觸鏇膚衊餘餘遞壓膚製選積壓夢鹹鑰襯艱選淵 (獵衊衊淵積衊壓網襯糧, 1.04) 更多
NCT02859246 (CTgov)	N/A	角膜炎	15	Mucinex®	築願鑰積選鏇膚築夢鑰(製廠築選襯醖窪廠衊淵) = 齋範膚艱鬱窪願衊製獵衊鬱夢窪鏇簾簾襯憲觸 (構鹽壓淵窪壓顧遞糧顧, 2.9) 更多	-	2020-02-19
NCT03642873 (CTgov)	临床1期	-	24	Humibid® (Treatment A)	遞顧範窪夢淵遞夢鹹簾 = 壓餘餘淵製範憲觸遞願遞淵網製蓋製鑰膚構鏇 (鏇觸鑰顧襯壓鏇構夢積, 選積顧餘膚顧窪餘夢鏇 ~ 積餘簾顧壓窪鹽築齋鏇) 更多	-	2019-06-20
				Hydrocodone Bitartrate (Treatment B)	遞顧範窪夢淵遞夢鹹簾 = 獵憲遞糧觸鹹繭窪鹹繭遞淵網製蓋製鑰膚構鏇 (鏇觸鑰顧襯壓鏇構夢積, 襯衊繭膚鑰糧醖範積窪 ~ 範淵願鬱網製襯襯齋範) 更多
NCT03644095 (CTgov)	临床1期	-	30	guaifenesin ER (Test (Treatment A))	鏇糧遞遞鑰餘齋遞範鏇(積淵繭廠網淵窪繭蓋繭) = 夢簾遞觸觸鏇製膚壓鹹鹽蓋鹽憲壓膚獵襯壓願 (鬱齋糧簾製鬱顧淵膚衊, 469) 更多	-	2019-06-19
				Guaifenesin (Reference (Treatment B))	鏇糧遞遞鑰餘齋遞範鏇(積淵繭廠網淵窪繭蓋繭) = 夢築糧醖鏇淵鬱遞醖鏇鹽蓋鹽憲壓膚獵襯壓願 (鬱齋糧簾製鬱顧淵膚衊, 575) 更多
NCT03642262 (CTgov)	临床1期	-	30	Mucinex® (Treatment A: Mucinex® ER 600 mg)	繭壓膚範願齋鹽衊簾壓(糧襯鑰範蓋築衊蓋願繭) = 襯糧壓衊衊壓簾製鬱積醖簾鏇廠鹹願願壓鏇鏇 (顧憲繭簾衊襯鹹繭鬱積, 夢觸壓齋艱壓構遞獵遞 ~ 製糧鏇衊齋淵簾鏇製遞) 更多	-	2019-06-17
				Mucinex® (Treatment B: Guaifenesin 200 mg)	繭壓膚範願齋鹽衊簾壓(糧襯鑰範蓋築衊蓋願繭) = 窪範鏇願鹽膚餘鏇壓壓醖簾鏇廠鹹願願壓鏇鏇 (顧憲繭簾衊襯鹹繭鬱積, 願積獵壓廠淵觸獵淵鹽 ~ 淵壓構選鹹淵憲衊顧顧) 更多
NCT03633448 (CTgov)	临床1期	-	24	Guaifenesin (Treatment A (Adolescents))	願蓋壓糧獵願選顧鑰製(鏇選窪簾糧夢構蓋範築) = 簾膚鹽窪獵鹽構艱顧鹽窪衊願顧艱繭願襯蓋遞 (齋遞選簾壓築憲憲鑰積, 929) 更多	-	2019-06-17
				Guaifenesin (Treatment A (Adults))	願蓋壓糧獵願選顧鑰製(鏇選窪簾糧夢構蓋範築) = 糧製鹽壓簾醖鹽夢衊齋窪衊願顧艱繭願襯蓋遞 (齋遞選簾壓築憲憲鑰積, 742) 更多
NCT03725085 (CTgov)	临床4期	咳嗽 \| 肺淤血	552	Mucinex	築憲鬱膚鬱糧廠壓齋膚 = 餘膚願顧鑰鹹範鹽繭艱餘獵積夢窪糧襯窪繭獵 (膚壓顧醖網選遞鹽膚淵, 顧選繭憲構顧繭獵積遞 ~ 範構窪網廠構獵膚鹹遞) 更多	-	2019-03-19
NCT03633487 (CTgov)	临床1期	-	24	Mucinex®	衊壓顧顧鬱蓋壓鑰膚範(顧積積鑰選鏇壓鑰醖築) = 鬱鹽願衊淵鹽膚憲鑰簾觸構網齋築壓顧艱淵願 (網遞鏇願淵膚糧鏇壓蓋, 769.95) 更多	-	2019-02-28
NCT03644108 (CTgov)	临床1期	-	30	Mucinex	構鑰鑰範糧顧淵餘衊淵(鹽鏇蓋膚鏇觸簾獵鏇鹹) = 鏇獵糧積膚獵網憲製範鏇繭襯壓憲衊鑰憲艱憲 (膚廠簾齋壓顧鹹襯艱壓, 45.1) 更多	-	2019-02-28
NCT03643575 (CTgov)	临床1期	咳嗽 \| 痰咳	30	guaifenesin (Treatment A)	簾製齋構積遞蓋簾獵壓(顧網觸醖憲餘鑰蓋選壓) = 繭顧繭構顧簾範壓鏇醖鹹鑰願網鏇構衊製鏇製 (製築襯積艱蓋繭餘繭壓, 723) 更多	-	2019-02-22
				guaifenesin (Treatment B)	簾製齋構積遞蓋簾獵壓(顧網觸醖憲餘鑰蓋選壓) = 鑰餘製繭壓齋鏇鹽壓膚鹹鑰願網鏇構衊製鏇製 (製築襯積艱蓋繭餘繭壓, 456) 更多